Skip to content

5E Advanced Materials, Inc. FEAM Accounts Payable And Accrued Liabilities Change Related To Equity Issuance Costs

Accounts Payable And Accrued Liabilities Change Related To Equity Issuance Costs at other companies

Biodesix, Inc. logo
Biodesix, Inc.BDSX
$64K+3,557%
Regenxbio logo
RegenxbioRGNX
$148K+3.5%
Dogwood Therapeutics logo
Dogwood TherapeuticsDWTX
$26.57K
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$92.75K
Owlet logo
OwletOWLT
$0-100%
CuriosityStream logo
CuriosityStreamCURI
$44.5K

Other financials

Income statement

See full
Operating income-$12.3M-20.5%
Net income-$12.1M-330%
EPS (diluted)-$0.35+63.9%

Balance sheet

See full
Cash & equivalents$25.4M+530%
Total debt$123.0K-52.3%
Total equity$73.0M+10.2%
Total assets$78.1M+6.4%

Cash flow

See full
Operating cash flow-$4.3M+25.5%
CapEx$4.3M+4,563%
Free cash flow-$8.6M-47.8%

Valuation

See full
Market cap$57.71M-19.1%
Enterprise value$32.44M-52.6%

Returns & leverage

See full
Return on equity-62.4%-12.3pp
Debt / equity0.0×
Current ratio6.5×+5.8×

Where this comes from

Reported directly by 5E Advanced Materials, Inc. in its filing.

Tagged under the XBRL concept feam:AccountsPayableAndAccruedLiabilitiesChangeRelatedToEquityIssuanceCosts.

The official record: 5E Advanced Materials, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about 5E Advanced Materials, Inc.'s accounts payable and accrued liabilities change related to equity issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 5E Advanced Materials, Inc.'s accounts payable and accrued liabilities change related to equity issuance costs?
5E Advanced Materials, Inc. (FEAM) reported accounts payable and accrued liabilities change related to equity issuance costs of $372K in Q1 2026.
What does accounts payable and accrued liabilities change related to equity issuance costs mean?
Represents the change in liabilities associated with costs incurred during equity financing activities, such as underwriting or legal fees. This metric highlights the non-cash impact of equity issuance processes on the balance sheet. It is useful for understanding the efficiency of capital raising efforts and their associated administrative burdens.